

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE


Single Technology Appraisal

Brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325]

Provisional Stakeholder List

Provisional Consultees	Provisional Commentators (no right to submit or appeal)
Company	General
Brexucabtagene autoleucel (Gilead	All Wales Therapeutics and Toxicology
Sciences Ltd)	Centre
Patient/carer groups	Allied Health Professionals Federation
African Caribbean Leukaemia Trust	Board of Community Health Councils in
Anthony Nolan	Wales
Black Health Agency for Equality	British National Formulary
Blood Cancer UK	Care Quality Commission
Cancer Black Care	Cell and Gene Therapy Catapult
Cancer Equality	Department of Health - Northern Ireland
Cancer52	Healthcare Improvement Scotland
DKMS	Medicines and Healthcare products
 Independent Cancer Patients Voice 	Regulatory Agency
 Kevin Karawa Leukaemia Trust 	National Association of Primary Care
Leukaemia Cancer Society	National Pharmacy Association
Leukaemia Care	NHS Confederation
Lymphoma Action	Scottish Medicines Consortium
Macmillan Cancer Support	Welsh Government
Maggie's Centres	Welsh Health Specialised Services
Marie Curie	Committee
South Asian Health Foundation	
Specialised Healthcare Alliance	Possible comparator companies
Tenovus Cancer Care	ADVANZ Pharma (prednisolone)
WMUK	 Baxter Healthcare (cyclophosphamide, doxorubicin)
Healthcare professional groups	BeiGene UK (zanubrutinib)
Association of Cancer Physicians	Celltrion Healthcare UK (rituximab)
British Geriatrics Society	Chemidex Pharma (prednisolone)
British Institute of Radiology	Dr Reddy's Laboratories UK
British Oncology Pharmacy	(bendamustine)
Association	Hospira UK (cytarabine, vincristine)
British Psychosocial Oncology Society	Jazz Pharmaceuticals UK (cytarabine)
British Society for Haematology	Karo Pharma AB (prednisolone)
British Society of Blood and Marrow	Logixx Pharma (prednisolone)
Transplantation and Cellular Therapy	Medac GmbH (doxorubicin)

Provisional stakeholder list for the evaluation of brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325] Issue date: September 2024



Provisional Consultees	Provisional Commentators (no right to submit or appeal)
 British Society of Interventional Radiology British Transplantation Society Cancer Research UK NHS Blood and Transplant Royal College of General Practitioners Royal College of Nursing Royal College of Pathologists Royal College of Physicians Royal College of Radiologists Royal Pharmaceutical Society Royal Society of Medicine Society and College of Radiographers UK Clinical Pharmacy Association UK Cutaneous Lymphoma Group UK Oncology Nursing Society Others Department of Health and Social Care NHS England 	 Phoenix Labs (prednisolone) Pfizer (rituximab, doxorubicin) Roche (rituximab) RPH Pharmaceuticals AB (prednisolone) Sandoz (rituximab, cyclophosphamide) Seacross Pharmaceuticals (bendamustine, doxorubicin) Strides Pharma (prednisolone) Wockhardt UK (prednisolone) Zentiva (bendamustine, prednisolone) Relevant research groups Cochrane Haematology Group Genomics England Institute of Cancer Research Leukaemia Busters Leukaemia UK Lymphoma Research Trust MRC Clinical Trials Unit National Institute for Health Research Associated Public Health groups Public Health Wales UK Health Security Agency

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.

Definitions:


Consultee or commentator stakeholders are provisional until a signed Confidentiality Agreement & Undertaking form is submitted to NICE at the evaluation stage. Participating stakeholders will be listed on the project information page for the evaluation.

Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient

Provisional stakeholder list for the evaluation of brexucabtagene autoleucel for treating relapsed or refractory mantle cell lymphoma after 2 or more systemic treatments [ID6325] Issue date: September 2024





organisations; the Department of Health and Social Care and relevant NHS organisations in England.

The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.